STSA-1301 / Staidson Biopharma - LARVOL DELTA

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd.

New P1/2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Recruiting ➔ Completed

Trial completion • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura • IL6 • TNFA

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura • IL6